INTRODUCTION {#sec1}
============

Alcohol use disorder (AUD) is a chronic relapsing brain disease characterized by compulsive alcohol use, loss of control over alcohol intake, and a negative emotional state when not using ([@ref1]). In 2010, alcohol-attributable cancer, liver cirrhosis, and injury caused 1,500,000 deaths or 2.8% of all deaths worldwide ([@ref3]). According to the World Health Organization, Lithuania is a leading country in pure alcohol consumption in the world with 18.2 litres of pure alcohol consumption per capita within a calendar year ([@ref2]).

Recent studies have shown strong evidence to support the hypothesis that AUD is a complex disease with hereditary and environmental effects, and with 50--60% heritability ([@ref4]). Genes involved in vulnerability to AUD include genes that act on common metabolic pathways involved in addiction to different substances and predisposition to other psychiatric disorders. Alcohol-specific genes include genes for metabolic enzymes involved in the metabolism of ethanol, as well as genes encoding gatekeeper molecules such as receptors or neurotransmitters ([@ref5]).

An understanding of the molecular mechanisms and metabolic pathways involved in excessive alcohol consumption is crucial for treatment of and screening for AUD. The aim of this study was to find novel genome variants associated with AUD in a Lithuanian cohort.

METHODS {#sec2}
=======

Single nucleotide polymorphism array analysis was performed on 294 selected Lithuanians, whose family members were born in Lithuania for three generations, using Illumina HiScanSQ™ genome analyzer. The case groups (alcohol drinker group) and the control (non-drinker group) were formed based on questionnaire. Descriptive statistics of the study groups are shown in [Table 1](#T1){ref-type="table"}.

DNA was extracted from venous blood samples using either MagneSil® Genomic, Large Volume System (Promega Corp., USA) automated for the TECAN Freedom EVO® platform (TECAN Group Ltd., Switzerland), according to the manufacturer's instructions, or the phenol-chloroform extraction method. We used Illumina HiScanSQ™ platform and Illumina HumanOmniExpress-12 v1.1 array, adhering to the Infinium® HD Assay Ultra Protocol Guide (Illumina Inc., USA). The genotyping data visualization, primary quality control analysis, filtering, and output file generation were accomplished using the Illumina GenomeStudio v2011.1 Genotyping Module software.

Genotyping data contained 98 genome variants from 23 genes associated with AUD. Genome variants were picked for further investigation from these genes: *ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH1A1, ALDH2, CYP2E1, CHRNA3, CHRNA5, GABRA2, OPRM1, HTR2A, HTR3B, NALCN, COMT, DPYSL2, GAD2, SLC6A4, ANKK1, NPY*. Genome variants, whose minor allele frequency was larger than 0.01, were selected for frequency evaluation in the Lithuanian population. The Hardy-Weinberg equilibrium and allele/genotype frequencies were determined using the PLINK v1.90b3.44 64-bit (2016-11-17) software ([@ref6]). Pearson's chi-squared test and Fisher's exact test (for genotype counts less than 5) were used to evaluate the results.

RESULTS {#sec3}
=======

Minor allele frequency (MAF) evaluation was done and only 65 genome variants with MAF greater than 0.01 were selected for further analysis. Three of them did not meet conditions of the Hardy-Weinberg equilibrium. [Table 2](#T2){ref-type="table"} shows descriptive statistics of single nucleotide variants (SNV) used in the study.

Allele frequency analysis showed that rs686141T\>C genome variant found in *NALCN* gene showed statistically significant difference in relative alternative allele frequency between the study groups. Relative allele frequency of rs686141T\>C variant was 0.27 in the alcohol drinker group and 0.38 in the non-drinker group (OR = 0.60 (CI 95% 0.37--0.98), *p* = 0.0408).

###### 

Descriptive statistics of the study groups

  Sex      Case group (*n* = 253), (%)   Control group (*n* = 41), (%)   Total (*N* = 294), (%)
  -------- ----------------------------- ------------------------------- ------------------------
  Female   120 (47.43)                   25 (60.98)                      145 (49.32)
  Male     133 (52.57)                   16 (39.02)                      149 (50.68)

###### 

SNV statistics of 65 genome variants used in analysis

  SNV                  Counts (%)
  -------------------- ------------
  Intronic variants:   33 (53.23)
  UTR 3' variants      28 (84.84)
  UTR 5' variants      5 (15.16)
  Exonic variants:     29 (46.77)
  Synonymous           11 (37.93)
  Nonsynonymous        17 (58.62)
  Stopgain             1 (3.48)

After the evaluation of genotype frequencies in the study groups, only one genome variant rs6354C\>A in the *SLC6A4* gene showed statistically significant difference between the study groups. Variant genotype distribution (CC/CA/AA) was 9/72/172 in the case group and 5/7/29 (*p* = 0.0264) in the control group.

###### 

Table of results of allele frequency evaluation in the study groups

  Gene           SNV            Variant                                                  Case group MAF[\*](#TF1){ref-type="table-fn"}   Control group MAF[\*](#TF1){ref-type="table-fn"}   *p* value[†](#TF2){ref-type="table-fn"}   OR[‡](#TF3){ref-type="table-fn"}
  -------------- -------------- -------------------------------------------------------- ----------------------------------------------- -------------------------------------------------- ----------------------------------------- ----------------------------------
  *ADH5*         rs7669660      NM_000671:c.[\*](#TF1){ref-type="table-fn"}966T\>C       0.08                                            0.10                                               0.5257                                    0.77
  *ADH5*         rs11547772     NM_000671:c.[\*](#TF1){ref-type="table-fn"}775T\>G       0.05                                            0.05                                               0.8938                                    0.93
  *ADH5*         rs6827292      NM_000671:c.[\*](#TF1){ref-type="table-fn"}574T\>C       0.03                                            0.05                                               0.4919                                    0.68
  *ADH5*         rs1803037      NM_000671.4:c.[\*](#TF1){ref-type="table-fn"}417G\>A     0.05                                            0.05                                               0.8938                                    0.93
  *ADH4*         rs1042364      NM_000670.4:c.[\*](#TF1){ref-type="table-fn"}19A\>G      0.34                                            0.24                                               0.0982                                    1.57
  *ADH4*         rs1126673      NM_000670.4:c.1120G\>A                                   0.38                                            0.33                                               0.3833                                    1.25
  *ADH4*         rs1126672      NM_000670.4:c.1051C\>T                                   0.34                                            0.24                                               0.0982                                    1.57
  *ADH4*         rs1126671      NM_000670.4:c.925A\>G                                    0.38                                            0.33                                               0.3653                                    1.26
  *ADH7*         rs284787       NM_000673:c.[\*](#TF1){ref-type="table-fn"}749C\>T       0.24                                            0.28                                               0.3738                                    0.79
  *ADH7*         rs3805331      NM_000673:c.[\*](#TF1){ref-type="table-fn"}373T\>C       0.05                                            0.06                                               0.6708                                    0.81
  *ADH7*         rs971074       NM_000673.4:c.690G\>A                                    0.13                                            0.15                                               0.7696                                    0.91
  *ADH7*         rs17537595     NM_000673:c.-40T\>C                                      0.16                                            0.15                                               0.7518                                    1.11
  *OPRM1*        rs6912029      NM_000914:c.-172C\>A                                     0.04                                            0.05                                               0.5588                                    0.72
  *OPRM1*        rs1799971      NM_000914.4:c.118A\>G                                    0.07                                            0.07                                               0.9988                                    1.00
  *OPRM1*        rs563649       NM_001145287:c.-3004G\>A                                 0.10                                            0.10                                               0.9836                                    0.99
  *OPRM1*        rs650245       NM_001145286:c.[\*](#TF1){ref-type="table-fn"}4A\>G      0.08                                            0.10                                               0.6153                                    0.82
  *IPCEF1*       rs9479767      NM_001130699:c.[\*](#TF1){ref-type="table-fn"}4435T\>C   0.46                                            0.54                                               0.1777                                    0.73
  *IPCEF1*       rs17277929     NM_001130699:c.[\*](#TF1){ref-type="table-fn"}3050T\>C   0.09                                            0.07                                               0.5631                                    1.30
  *IPCEF1*       rs2236256      NM_001130699:c.[\*](#TF1){ref-type="table-fn"}2523G\>T   0.46                                            0.54                                               0.1777                                    0.73
  *IPCEF1*       rs2236259      NM_001130699:c.[\*](#TF1){ref-type="table-fn"}2070T\>C   0.46                                            0.54                                               0.1777                                    0.73
  *NPY*          rs16139        NM_000905.3:c.20T\>C                                     0.06                                            0.02                                               0.1963                                    2.52
  *DPYSL2*       rs708621       NM_001197293.2:c.1821T\>C                                0.30                                            0.26                                               0.4142                                    1.25
  *DPYSL2*       rs1058332      NM_001197293:c.[\*](#TF1){ref-type="table-fn"}1071G\>A   0.10                                            0.05                                               0.1586                                    2.09
  *DPYSL2*       rs920633       NM_001197293:c.[\*](#TF1){ref-type="table-fn"}1557A\>G   0.14                                            0.09                                               0.1575                                    1.79
  *DPYSL2*       rs17666        NM_001197293:c.[\*](#TF1){ref-type="table-fn"}2236A\>G   0.29                                            0.29                                               0.9738                                    1.01
  *ALDH1A1*      rs8188000      NM_000689:c.[\*](#TF1){ref-type="table-fn"}455T\>C       0.07                                            0.11                                               0.2225                                    0.62
  *ALDH1A1*      rs13959        NM_000689.4:c.225C\>T                                    0.42                                            0.35                                               0.2507                                    1.33
  *GAD2*         rs2236418      NM_000818:c.-243A\>G                                     0.21                                            0.21                                               0.9968                                    1.00
  *CYP2E1*       rs6413419      NM_000773.3:c.535G\>A                                    0.01                                            0.00                                               0.2840                                    NA
  *CYP2E1*       rs2515641      NM_000773.3:c.1263C\>G                                   0.13                                            0.09                                               0.2695                                    1.58
  *ANKK1*        rs17115439     NM_178510.1:c.255T\>C                                    0.32                                            0.25                                               0.2264                                    1.39
  *ANKK1*        rs4938013      NM_178510.1:c.453A\>C                                    0.33                                            0.26                                               0.2061                                    1.41
  *ANKK1*        rs7118900      NM_178510.1:c.715G\>A                                    0.16                                            0.12                                               0.3990                                    1.35
  *ANKK1*        rs4938016      NM_178510.1:c.1324G\>C                                   0.36                                            0.29                                               0.2126                                    1.38
  *ANKK1*        rs2734849      NM_178510.1:c.1469A\>G                                   0.48                                            0.59                                               0.0719                                    0.65
  *ANKK1*        rs2734848      NM_178510.1:c.1683C\>T                                   0.18                                            0.15                                               0.4843                                    1.26
  *HTR3B*        rs1176744      NM_006028.4:c.386A\>C                                    0.28                                            0.29                                               0.7644                                    0.92
  *HTR3B*        rs17116138     NM_006028.4:c.547G\>A                                    0.04                                            0.05                                               0.5588                                    0.72
  *HTR2A*        rs9595552      NM_001165947:c.[\*](#TF1){ref-type="table-fn"}1542T\>C   0.07                                            0.06                                               0.8508                                    1.10
  *HTR2A*        rs6314         NM_000621.4:c.1354C\>T                                   0.07                                            0.06                                               0.7846                                    1.14
  *HTR2A*        rs6313         NM_000621.4:c.102C\>T                                    0.32                                            0.37                                               0.3725                                    0.80
  *NALCN*        rs8922         NM_052867.2:c.[\*](#TF1){ref-type="table-fn"}1454T\>G    0.22                                            0.22                                               0.9656                                    0.99
  *NALCN*        rs682767       NM_052867.2:c.[\*](#TF1){ref-type="table-fn"}1018T\>C    0.38                                            0.45                                               0.2296                                    0.75
  *NALCN*        rs682666       NM_052867.2:c.[\*](#TF1){ref-type="table-fn"}946C\>T     0.39                                            0.45                                               0.2578                                    0.76
  *NALCN*        rs9557581      NM_052867.2:c.[\*](#TF1){ref-type="table-fn"}931A\>G     0.38                                            0.45                                               0.2296                                    0.75
  *NALCN*        rs1289556      NM_052867.2:c.4416A\>C                                   0.38                                            0.33                                               0.4210                                    1.23
  *NALCN*        rs17677552     NM_052867.2:c.3714C\>T                                   0.37                                            0.30                                               0.2721                                    1.33
  ***NALCN***    **rs686141**   **NM_052867.2:c.3570T\>C**                               **0.27**                                        **0.38**                                           **0.0409**                                **0.60**
  *CHRNA3*       rs660652       NM_000743:c.[\*](#TF1){ref-type="table-fn"}1114T\>C      0.36                                            0.33                                               0.5473                                    1.16
  *CHRNA3*       rs472054       NM_000743:c.[\*](#TF1){ref-type="table-fn"}952T\>C       0.36                                            0.33                                               0.5536                                    1.16
  *CHRNA3*       rs578776       NM_000743:c.[\*](#TF1){ref-type="table-fn"}546C\>T       0.25                                            0.24                                               0.8608                                    1.05
  *CHRNA3*       rs1051730      NM_000743.4:c.645C\>T                                    0.38                                            0.43                                               0.3940                                    0.81
  *CHRNA3*       rs8040868      NM_000743.4:c.159A\>G                                    0.42                                            0.46                                               0.4470                                    0.83
  *CHRNA3*       rs8192475      NM_000743.4:c.110G\>A                                    0.03                                            0.04                                               0.8898                                    0.92
  *SLC6A4*       rs3813034      NM_001045:c.[\*](#TF1){ref-type="table-fn"}670T\>G       0.43                                            0.48                                               0.4897                                    0.85
  *SLC6A4*       rs1042173      NM_001045:c.[\*](#TF1){ref-type="table-fn"}463T\>G       0.43                                            0.48                                               0.4897                                    0.85
  ***SLC6A4***   **rs6354**     **NM_001045:c.-922G\>T**                                 **0.18**                                        **0.21**                                           **0.5214**                                **0.83**
  *COMT*         rs4633         NM_000754.3:c.186C\>T                                    0.46                                            0.51                                               0.3659                                    0.81
  *COMT*         rs4680         NM_000754.3:c.472G\>A                                    0.46                                            0.51                                               0.3659                                    0.81
  *COMT*         rs769224       NM_000754.3:c.597G\>A                                    0.04                                            0.07                                               0.1405                                    0.50
  *COMT*         rs165599       NM_000754.3:c.[\*](#TF1){ref-type="table-fn"}522G\>A     0.35                                            0.44                                               0.1277                                    0.69
  *COMT*         rs165728       NM_000754.3:c.[\*](#TF1){ref-type="table-fn"}764C\>T     0.11                                            0.17                                               0.1193                                    0.60

\* MAF -- Minor Allele Frequency

† *p* value -- Pearson's Chi squared test *p* value

‡ OR -- Odds Ratio

Statistically significant results are bolded

DISCUSSION {#sec4}
==========

In this study, we examined the association of AUD with genome variants found in genes related to various enzymes, that are responsible for the metabolism of ethanol, neurotransmitters, or function of the receptors. Our data revealed novel genome variants in the association of *NALCN* and *SLC6A4* genes with AUD. rs686141T\>C variant has never been studied before in similar AUD-related studies. Meanwhile, rs6354C\>A variant was known but never studied more extensively. As a further matter, *NALCN* and *SLC6A4* genes were considered responsible for depressive phenotype and other psychiatric diseases.

In similar studies, it was hypothesized that the aetiology of both psychiatric diseases and AUD was related to a dysfunctional serotonergic system ([@ref7], [@ref8]). Serotonin is a monoamine known to affect anxiety, cognition, reward, emotion, drug responses, and stress ([@ref9], [@ref10]). The role of serotonin in alcohol consumption has been studied in animal models. The serotonergic system has been found to have only a minor role in mediating sensitivity to high doses of alcohol, but to be crucial for the development of alcohol reinforcement ([@ref8], [@ref11]). A study by Jiekun Yang and Ming D. Li showed that haplogroup formed by rs6354C\>A, rs25528C\>A, rs2066713C\>T, rs8071667A\>G, and rs16965623T\>C showed a marginal association with AUD under the additive model (*P* = 0.005) ([@ref12]).

Recent Genome Wide Association Study (GWAS) performed in a group of 2322 individuals demonstrated significant SNV (rs17484734G\>A) located in the *NALCN* gene and a high risk of AUD ([@ref13]). *NALCN* is a protein that contributes to the resting membrane potential in these neurons by eliciting a depolarizing current to counterbalance the hyperpolarizing current ([@ref14], [@ref15]). Changes in this system might be associated with substance addiction and AUD. A rodent study showed that mice that carry a hypomorphic mutation in the *Unc-79* gene (one of the *NALCN* subunits) voluntarily consume more ethanol than wild-type mice ([@ref16]).

The identification of novel genome variants and AUD is important to improve our ability to predict the risks and treatment responses, to develop new treatments and screening techniques.

CONCLUSIONS {#sec5}
===========

We analysed 23 genes associated with AUD and identified two novel genome variants (rs686141T\>C and rs6354C\>A). The study shows that genome analysis is an important tool in AUD research. The results supplement known information about genes associated with AUD.
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